Purpose-built for oncology and rare diseases therapies.
Why MediSights
Purpose-built for complex therapy areas
Oncology and rare diseases are different:
Evidence evolves rapidly
Treatment decisions involve trade-offs and uncertainty
Guidelines, real-world behavior, and physician beliefs often diverge
Specialists are global and segmented in ways that matter
Generic research platforms weren't built for this complexity. MediSights is.
What Makes Us Different
Depth at scale
We don't sacrifice rigor for speed. Our approach captures genuine clinical reasoning—beliefs, trade-offs, uncertainty—while scaling to hundreds or thousands of doctors.
Clinical grounding
Oncology and rare disease ontologies constrain our AI to prevent hallucinations. We speak the language of lines of therapy, biomarkers, regimens, and clinical endpoints.
Evidence traceability
Every insight links back to the underlying doctor conversation. Your teams can verify findings themselves. No black-box outputs.
Pharma-grade compliance
Security, privacy, adverse event detection, audit trails—built in from day one.
Longitudinal by design
Track how beliefs and behaviors change over time. Prove whether your strategies actually shifted the market.
Global-ready
Multi-market comparisons, multi-language support, and workflows designed for global brand teams from the start.
Why Traditional Research Falls Short—And How MediSights Solves It
Too Slow
Traditional market research takes 6–8 months from kickoff to final insights. By the time results arrive, the market has moved.
How MediSights solves it: We deliver deep, clinically grounded insights in weeks through AI-powered analysis—without sacrificing rigor or compliance.
Can't Verify the Truth
Research outputs arrive as static PowerPoint decks. AI tools give you answers but hide the underlying evidence. You're forced to trust without verifying.
How MediSights solves it: Every insight links directly back to the source doctor conversation. Your teams can explore, verify, and interrogate the evidence themselves.
Built for Generic Use Cases, Not Pharma
Generic AI tools lack clinical grounding and weren't designed for regulated industries. They hallucinate products, biomarkers, and endpoints. They can't handle adverse event detection or pharma-grade audit requirements.
How MediSights solves it: Purpose-built for oncology and rare diseases with curated medical ontologies that prevent hallucinations. Security, privacy, AE detection, and compliance built-in from day one.
Our Focus
Oncology and rare diseases. Always.
We don't try to be everything to everyone. We're the oncology and rare diseases data and insights platform—and we're building the deepest clinical grounding, the richest doctor intelligence, and the most rigorous compliance for these therapy areas.
If you're launching or growing brands in oncology or rare diseases, we speak your language.